Inorganic, Synthetic, Natural, and Innovative Hybrid Hydrogen Sulfide Donors and Inhibitors of Its Biosynthesis in the Treatment of Central and Peripheral Nervous System Injuries: A Systematic Analytical Review
Hydrogen sulfide (H<sub>2</sub>S) is a gasotransmitter that plays a crucial role in regulating pathological processes following injury to the central and peripheral nervous systems. This review systematizes current data on various classes of H<sub>2</sub>S donors and inhibitors of its biosynthesis in neurotrauma and related experimental models. Inorganic donors (e.g., NaHS, Na<sub>2</sub>S, and STS) rapidly suppress oxidative stress and inflammation, supporting the recovery of synaptic plasticity and cognitive function. Organic donors (e.g., GYY4137, ACS67, ACS84, SPRC, ADT-OH and its derivatives, S-memantine, and MTC) provide sustained H<sub>2</sub>S release, stabilize the blood-brain barrier, and exhibit antiapoptotic activity. Natural donors (e.g., DADS, DATS, and SAMe) demonstrate high biocompatibility, inhibit pyroptosis, and enhance antioxidant defense mechanisms. Hybrid systems-including nanoparticles and hydrogels-enable targeted delivery and prolonged action, thereby stimulating regeneration and angiogenesis. Thiol-activated donors (e.g., COS/H<sub>2</sub>S and AlaCOS) allow controlled H<sub>2</sub>S release, offering broad opportunities for precise modulation of its concentration within target tissues. Inhibitors (e.g., AOAA, PAG, oxamic hydrazide 1, L-aspartic acid, benserazide, and NSC4056) of H<sub>2</sub>S biosynthesis underscore the physiological importance of this gasotransmitter, as their administration enhances neuroinflammation and diminishes neuroprotection. The analysis reveals a general pattern: all classes of H<sub>2</sub>S donors effectively modulate key pathological mechanisms, differing in their rate, duration, and specificity of action. These findings highlight the therapeutic promise of H<sub>2</sub>S-based pharmacological agents in clinical neurotraumatology, while emphasizing the need for further research to optimize delivery systems, enhance efficacy, and minimize adverse effects.
Authors
- М. З. Гасанов (ORCID: https://orcid.org/0000-0001-5856-0404)
- Stanislav Sergeevich Bachurin (ORCID: https://orcid.org/0000-0002-4349-5897)
- В. С. Чулков (ORCID: https://orcid.org/0000-0002-0952-6856)
- Stanislav Rodkin (ORCID: https://orcid.org/0000-0003-4036-5410)
- Inna N. Vasileva (ORCID: https://orcid.org/0000-0001-8335-1380)
- Sergey Golovin (ORCID: https://orcid.org/0000-0002-1929-6345)
- А. А. Толмачева (ORCID: https://orcid.org/0000-0003-1687-4100)
- Антон В. Лисовин (ORCID: https://orcid.org/0000-0001-7788-288X)
Institutions
- Novosibirsk State Medical University (RU)
- Sechenov University (RU)
- Don State Technical University (RU)
- Yaroslav-the-Wise Novgorod State University (RU)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3390/ijms262411842
- Citations
- 1
- Primary Topic
- Sulfur Compounds in Biology
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Russian Science Foundation